As mobile health advances help engage patients as active partners in their healthcare, these technologies can potentially harness that engagement and connect them with interventions, said Leah Sparks, co-founder and CEO of Wildflower Health.
As mobile health advances help engage patients as active partners in their healthcare, these technologies can potentially harness that engagement and connect them with interventions, said Leah Sparks, co-founder and CEO of Wildflower Health.
Transcript (slightly modified)
What do you see in the future of mHealth?
That’s a great question a lot of people are asking, and I think there’s a lot of opportunity in the market. mHealth is already being deployed with consumers to track all of these data signals related to their health, but all of that, much of that data still living very much in the consumer realm. And where I think the opportunities are right now, are to bring that further into the healthcare system and really help unleash that data for providers and payers and put it in context, so the consumer can really partner with the healthcare system to use all that data to really make differences in their health.
How do you think mHealth technology will increase patient engagement?
Well, I think it already is increasing patient engagement. I think there are already a lot of studies and data points, even if they’re anecdotal at this point, that show that as people are tracking things and using devices and using mobile apps for their health, they are more engaged around it personally. Again, I think the next leap forward needs to be, it’s taking that engagement and harnessing it in a way that’s evidence-based and helps them connect with evidence-based interventions, again, with their provider or other clinical services.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More